Videos |View More
Roswell Park Comprehensive Cancer Center Interventional Pulmonologist Nathaniel Ivanick, MD, Discusses Use of New Hybrid Metallic Y Stent to Treat a Severe Airway Obstruction Caused by a Malignant Lung Tumor
Chair of Thoracic Surgery at Roswell Park, Dr. Sai Yendamuri, shares insights into an exciting phase I trial evaluating the side effects of intraoperative photodynamic therapy with porfimer sodium in enhancing the response to immunotherapy ...
Navigating to the Periphery of the Lung: A Robotic Bronchoscopy Demonstration
As the first to bring this technology to patients in New York State in July 2020, Dr. Ivanick has now performed more than 100 bronchoscopies using the platform, more than any other provider in New York State.
Using 3D Technology to Improve Patient Care
Equipped with FDA-approved software, a tablet computer and a pen, doctors at Roswell Park Comprehensive Cancer Center can transform a flat CT image of a tumor and the area around it into a computerized 3D image that can be rotated or flipped ...
What if you could treat disease that you can’t see or feel while performing surgery on patients? The Department of Thoracic Surgery at Roswell Park Comprehensive Cancer Center has found early success in using a pioneering surgical technique ...
The Role of Interventional Pulmonology in Cancer Care: Introducing Dr. Nathaniel Ivanick
Nathaniel Ivanick, MD, is a highly skilled interventional pulmonologist specializing in pulmonary medicine. As an interventional pulmonologist, Dr. Ivanick treats patients with a variety of malignant and non-malignant thoracic disease.
News |View More
Career Opportunity: Join Our Roswell Park Team
Roswell Park is currently seeking an accomplished leader to serve as the Clinical Chief for Thoracic Medical Oncology to spearhead patient care, research, and education advancements.
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
A phase 1/1b, open-label clinical trial underway at Roswell Park Comprehensive Cancer Center is taking a new approach to targeting KRAS G12C, the most common mutation in non-small cell lung cancer (NSCLC) and one that is sometimes present ...